2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy?

The 2024 European Society of Cardiology Congress in London was set to unveil four highly anticipated guidelines dealing, specifically, with atrial fibrillation, chronic coronary syndromes ( CCSs) , elevated blood pressure/hypertension, and peripheral arterial/aortic diseases.The 2024 ESC guidelines for the management of CCS were particularly awaited, 1 given significant advances since the previous version in 2019. 2 The new guidelines introduce a more precise classification of CCS, based on the underlying mechanisms of myocardial ischaemia-from epicardial to microvascular, each of which may be structural, functional or both.They also progress towards a stratified and patient-centred approach to the diagnosis and treatment of the disease.Several updates on cardiovascular pharmacotherapy are of significant impact on clinical practice.The present Pharmapulse therefore summarizes the key pharmacotherapy updates introduced by the new CCS guidelines.